LPL Financial’s Akero Therapeutics AKRO Stock Holding History

LPL Financial’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-4,791	Closed	-$256K	–	5800
2025 Q2	$256K	Sell	4,791 -1,434	-23%	-$65.2K	﹤0.01%	4896
2025 Q1	$252K	Buy	+6,225	New	+$264K	﹤0.01%	4697

Other funds holding AKRO

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LPL Financial's AKRO Position: Q3 2025 in Review

LPL Financial sold out of Akero Therapeutics (AKRO) in Q3 2025, closing a stake of 4,791 shares — an estimated $256K sold.

LPL Financial first reported a position in AKRO in Q1 2025 and held it in 2 quarters. The position peaked at $256K in Q2 2025. 265 funds tracked by Wall St. Rank hold AKRO as of Q3 2025.

LPL Financial reported no remaining Akero Therapeutics position as of Q3 2025 after selling out during the quarter.
LPL Financial sold 4,791 Akero Therapeutics shares in Q3 2025, an estimated $256K.
LPL Financial first reported a position in Akero Therapeutics in Q1 2025 and held it in 2 quarters.
LPL Financial's Akero Therapeutics position peaked at $256K in Q2 2025.
265 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2025.

Based on LPL Financial's 13F filing for Q3 2025, filed 12 Nov 2025.